The threat of antimicrobial resistance causing drug-resistant infections and the escalating health, social and economic consequences are now becoming visible at a global level. Here, we discuss the economic and political considerations for creating a truly global and effective response to antimicrobial resistance.
A ntimicrobial resistance (AMR) is a growing public health threat, and if we cannot work together to find solutions, we could enter a postantibiotic era where advances in modern medicine would be jeopardized, resulting in over a third of deaths once again be due to infections. Recent modelling by the Independent Review on AMR, chaired by Lord O'Neill, has predicted that AMR will cause an additional 10 million deaths per year ( Fig. 1 ) and a loss of up to US$100 trillion from global GDP by 2050 1, 2 .The review's final report reinforces that AMR is a multifaceted and complex problem that cannot be tackled by one nation alone. Thus, combatting AMR will require sustained global action across a variety of sectors (human, agricultural and environmental) in order to understand, prevent and control resistance; to preserve existing treatments; and to develop and implement a variety of new solutions, including new or repurposed antibiotics, alternative therapies, diagnostics, and infection prevention and control measures.
While the emergence of AMR is a natural phenomenon that cannot be completely prevented, there are many things that we can do to reduce the speed at which AMR emerges and spreads globally. For instance, we need to use antibiotics appropriately in both human and animal settings -nearly a third of antibiotics prescribed by doctors in the United States are for infections that do not respond to these drugs 3 and in animals, antibiotics are widely used for growth promotion and infection prevention rather than for cure 4 . Better understanding of behavioural drivers behind inappropriate use will thus help us preserve the effectiveness of existing antibiotics while ensuring appropriate use of new solutions 5 when they become available. Similarly, we need to consider the environmental consequences of human and animal excretion and discharges from the manufacturing of these drugs on the emergence, selection, and spread of resistance. We also require cheap and rapid diagnostics so that we can detect all types of infections in a variety of settings and then tailor or amend treatment to offer best clinical practices aimed at reducing inappropriate use of antimicrobials. In addition to preserving existing treatments, we need new antibiotics and alternatives therapies, including vaccines to treat and prevent infections. Importantly, alongside these targeted strategies, we still need to improve basic sanitation, hygiene, and infection control measures in order to reduce the overall incidence of infectious disease and thus our dependency on the need for antimicrobial use in general.
Only through improved awareness of AMR across all of society will we get the public and political support needed to work together and implement the necessary policies to slow the emergence and spread of AMR and effectively respond to this growing public health issue. Developing and implementing policy in this area is a complex process that needs to be looked at holistically and involve multiple sectors. For example, when developing new polices around the use of antimicrobials, we need to ensure promotion of appropriate access to effective drugs without unintentionally limiting access where there is a clinical need. This balance between access and excess is crucial since antimicrobial access in low and middle income countries (LMICs) can be just as much of a concern as excess 6 ; indeed, more people are dying today in LMICs from lack of access to antimicrobials than drugresistant infections (although modelling predicts these areas will also be those most affected by AMR in the future (Fig. 1 
While large, it is important to put this into context: US$16 billion is less than 0.25% of annual total global medicine sales (about US$1 trillion) -and less than the US$20 billion which AMR costs the US medical system alone each year. Hence, given the major health, social and economic costs of AMR, additional public and private investment is required along with an effective informed resource allocation system. The current business model for antimicrobial drug and diagnostic development is no longer fit for purpose and as a result many companies have scaled back or redirected their investments to other more profitable areas. Thus, developing incentives to provide a more attractive end market for products is important. But this is only addressing one aspect of the problem, as we also need to stimulate and finance additional research and development at a global level. This is an exciting time as many activities are now underway nationally and globally involving both public and private partners. In the UK, focusing on early stage and multidisciplinary research, we have the UK Cross Research Council AMR Initiative, operating at a multilateral level across 22 member states through the Joint Programming Initiative on AMR (http:// www.jpiamr.eu), while the Newton Fund (http://www.newtonfund.ac.uk) participates globally and to date has worked with India and China specifically on AMR research. We also have the UK Department of Health Fleming Fund, which is a £265 million program focusing on improving laboratory capacity and diagnosis as well as data and surveillance of AMR in LMICs through a 'one health' approach, and the Global AMR Innovation Fund in which the UK government has committed £50 million to the start-up phase and is working in collaboration with China and the Bill and Melinda Gates Foundation. The UK Longitude Prize (https://longitudeprize.org) is a £10 million diagnostic prize fund, which aims to incentivize the development of a transformative point-of-care test that is rapid, accurate, affordable and easy to use anywhere in the world.
In the EU, the Innovative Medicines Initiative (IMI; https://www.imi.europa.eu) is Europe's largest public-private partnership mainly focusing on preclinical and clinical development and has allocated around €740 million specifically to AMR related projects 8 . Two new international product development partnerships have also been established: the Global Antibiotic Research and Development (GARD; http://www.dndi. org/diseases-projects/gard) partnership (up to €3 million for the incubation phase) to develop new antibiotic treatments and to promote their responsible use, while ensuring equitable access for all in need; and FIND (http://www.finddx.org), which is supporting diagnostic strategies to avoid the inappropriate use of antibiotics and other medicines. More recently, CARB-X (http://www.carb-x.org) has been announced which is a US$250 million US Biomedical Advanced Research and Development Authority fund with matched funds from the Wellcome Trust and also the UK AMR Centre focusing on progressing AMR products towards clinical development.
These projects are a step in the right direction and highlight how governments, organizations, and industry can coordinate investments to further their commitments to tackling AMR. They also highlight the need for governments to continue pursuing even more engagement and collaboration internationally; for example, the UNGA meeting on AMR in September 2016 emphasized the need for partners to share information to avoid duplication and ensure complementarity. Globally, we have a number of opportunities coming up over the next few months where governments can discuss and agree on the next steps for tackling AMR, including at the G20 and United Nations General Assembly High Level Meeting on AMR. The UK government is hopeful that out of these discussions, we will:
• See a declaration at the UN General Assembly ensuring impactful commitments and high-level international political momentum for multi-sectoral implementation (health, agriculture, environment, development, research and finance) of the WHO's Global Action Plan on Antimicrobial Resistance 9 in all countries.
• See strong commitments to take action to improve AMR surveillance and develop appropriate antimicrobial use guidelines.
• See strong commitments to increasing collaborative funding of research and development, and innovation across the whole complex area -including prevention, diagnosis and treatment of infections.
• Mobilize G20 support for addressing the antibiotic market failure through a global financing mechanism. As we have looked to initially secure commitments to address the market failure, we will now work together to develop a global solution in order to foster environments that incentivize drug and diagnostic development.
The UK is working closely with others to develop global solutions on AMR and highlight the need for collective action. It is clear that AMR is a multifactorial problem that individual countries cannot tackle alone; we all have a role to play, and we must share the responsibilities in overcoming this major societal threat together. ❐
